The First Case of 99mTc-FAPI Uptake in Optic Nerve Sheath Meningioma.

Autor:	Sahafi P; From the Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Jafari Zarrin Ghabaei F; From the Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Aryana K; From the Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Aledavood SA; Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Aghaee A; From the Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Jazyk:	angličtina
Zdroj:	Clinical nuclear medicine [Clin Nucl Med] 2024 Sep 01; Vol. 49 (9), pp. e453-e454.
DOI:	10.1097/RLU.0000000000005332
Abstrakt:	Abstract: This case study presents the first demonstration of FAPI ligand uptake in a patient with optic nerve sheath meningioma. The patient, a 23-year-old woman who had previously undergone surgery for refractory optic meningioma, was referred to our department for 177Lu-DOTATATE therapy. After 3 cycles of 177Lu-DOTATATE administration, her proptosis significantly decreased. Two months after her last therapeutic cycle, a 99mTc-FAPI scan was performed. The scan revealed a mass with moderately increased uptake in the left retro-orbital region. This study is believed to be the first to demonstrate FAPI ligand uptake in a patient with optic nerve sheath meningioma. Competing Interests: Conflicts of interest and sources of funding: none declared. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu